Revance Therapeutics Inc RVNC

NAS: RVNC | ISIN: US7613301099   14/11/2024
4,310 USD (+1,65%)
(+1,65%)   14/11/2024

12 augustus 2024 · Crown Laboratories and Revance Announce Entry Into Merger Agreement · Persbericht

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

26 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

18 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

29 september 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC · Persbericht

17 november 2022 · Nanostics Announces New Member of Board of Directors · Persbericht

5 februari 2022 · Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Revance Therapeutics, Inc. (RVNC) That a Securities Fraud Class Action Lawsuit Has Been Filed On Their Behalf · Persbericht

2 februari 2022 · RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

27 januari 2022 · RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

13 januari 2022 · REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC · Persbericht

13 januari 2022 · Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. · Persbericht

6 januari 2022 · REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC · Persbericht

4 januari 2022 · RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

3 januari 2022 · Lead Plaintiff Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. · Persbericht

31 december 2021 · ALERT: Revance Therapeutics, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - RVNC · Persbericht

30 december 2021 · REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC · Persbericht

16 december 2021 · Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC) · Persbericht

16 december 2021 · REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC · Persbericht

15 december 2021 · DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNC · Persbericht

14 december 2021 · RVNC SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed · Persbericht

Mijn selecties